| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 18,670 | 26,390 | 34,160 | 59,080 | 0 |
| Sales Growth | -29.25% | -22.75% | -42.18% | unch | unch |
| Net Income | -64,780 | -62,030 | -50,620 | -22,330 | -520 |
| Net Income Growth | -4.43% | -22.54% | -126.69% | -4,194.24% | unch |
Omniab Inc (OABI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO.
Fiscal Year End Date: 12/31